CoChat

Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose‐escalation study

Open access
Richardson, Paul G., Chanan‐Khan, Asher A., Alsina, Melissa, Albitar, Maher, Berman, David, Messina, Marianne, Mitsiades, Constantine S., Anderson, Kenneth C. · 2010 · British Journal of Haematology
Cited by 80

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Summary: Tanespimycin, a heat shock protein 90 (HSP90) inhibitor, induces apoptosis in drug‐sensitive and ‐resistant MM cell lines and in tumour cells from patients with relapsed MM. In this phase 1 dose‐escalation study, the safety, plasma pharmacokinetics, and biological/antitumour activity of tanespimycin were evaluated in heavily pretreated patients with relapsed/refractory MM. Tanespimycin (150–525 mg/m 2 ) was given on days 1, 4, 8, and 11 of each 3‐week cycle for up to 8 cycles. Non‐haematological AEs included diarrhoea (59%), back pain (35%), fatigue (38%), and nausea (35%); haematological AEs included anaemia (24%) and thrombocytopenia (21%). One patient (3%) achieved minimal response (MR), with a progression‐free survival (PFS) of 3 months, a 41% decrease from baseline in urine M protein, and a 33% decrease from baseline in serum M protein. Fifteen patients (52%) achieved SD with a median PFS of 2·1 months; 5/15 had reductions in serum M protein ranging from 7% to 38% and in urine M protein ranging from 6% to 91%. Mean HSP70 levels increased from day 1 h 0 to day 1 h 4 with further increases on day 11 h 0 and day 11 h 4, consistent with a therapeutic treatment effect. Tanespimycin monotherapy was well tolerated and demonstrated activity across all doses tested.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2141.2010.08265.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 80

Metadata

Authors
Richardson, P. G., Chanan‐Khan, A. A., Alsina, M., Albitar, M., Berman, D., Messina, M., Mitsiades, C. S., & Anderson, K. C.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2010-08
Volume
150
Issue
4
Pages
438-445
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W1562135226
Cited by
80
References
3
FWCI
8.62
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose‐escalation study. https://app.cochat.ai/papers/10.1111/j.1365-2141.2010.08265.x
The paper
Richardson, P. G., Chanan‐Khan, A. A., Alsina, M., Albitar, M., Berman, D., Messina, M., Mitsiades, C. S., & Anderson, K. C. (2010). Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose‐escalation study. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2010.08265.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.